Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a multi-institutional clinical trial showed.
The Accountability for Cancer Care through Undoing Racism and Equity (ACCURE) clinical trial—a prospective study designed to reduce gaps in cancer treatment completion and survival among Black and white patient populations— found that identifying and addressing obstacles that kept patients from finishing radiation treatments improved five-year survival rates for all patients and erased the survival gap between Black and white patients.
A new meta-analysis found that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.
A study presented at the American Society for Radiation Oncology annual meeting found that high-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases.
The time required to secure prior authorization approvals for radiation therapy treatments equates to a financial impact of more than $40 million annually for academic medical centers, according to a Vanderbilt University study.
Updated results from the TRACERx (Tracking Cancer Evolution through therapy (Rx)) lung cancer study further validated the value of liquid biopsy as a less invasive and more comprehensive approach to guiding personalized cancer treatment in the absence of detectable disease by clinical imaging.
The Oncology Center of Excellence and the Center for Drug Evaluation and Research have developed a publicly available database with information about accelerated approvals in oncology and hematologic malignancies.
FDA and the the European Medicines Agency accepted the Supplemental Biologics License Application and Type II Variation, respectively, for Kymriah (tisagenlecleucel) in adult patients with relapsed or refractory (r/r) follicular lymphoma after two prior lines of treatment. FDA also granted priority review to the sBLA for Kymriah in adult patients with r/r FL.
A skin cancer vaccination called IFx-Hu2.0 received FDA “fast track” designation to treat patients with advanced cutaneous melanoma who have not responded to other therapies and medication.
FDA took several actions to strengthen breast implant risk communication and help those who are considering breast implants make informed decisions.
